Protocols
ADP-0055-001-MAGE-A4-SURPASS Phase I OPEN TO ACCRUAL
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 as Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
ARCELLX-ACLX-001-DDBCMA Phase I OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
CARGO-CRG-022-101-LBCL Phase II OPEN TO ACCRUAL
An Open-label-Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22 Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy
CARIBOU-CAMMOUFLAGE-CB-011A-MM Phase I OPEN TO ACCRUAL
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
GSK-3377794-LTFU Phase I OPEN TO ACCRUAL
Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies
IIT-SHAH-IL7-IL15-CD20-19 Phase I/II OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
JNJ-MY4002-CARTINUE-LTFU Phase IV OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
LYELL-LYL-797-101 Phase I OPEN TO ACCRUAL
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid Tumor Malignancies
NOVARTIS-YTB323A12101 Phase I OPEN TO ACCRUAL
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
SOTIO-BOXR1030 Phase I/II OPEN TO ACCRUAL *
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors